PREDICT has identified RCC as a disease lacking predictive biomarkers for the most active therapeutic compounds targeting the mammalian target of rapamycin (mTOR) and vascular endothelial growth factor (VEGF) pathways. This evidence concerns the gene MTOR and renal cell carcinoma.